Clinical data | |
---|---|
Other names | GC-1 |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H24O4 |
Molar mass | 328.408 g·mol−1 |
3D model (JSmol) | |
| |
|
Sobetirome (GC-1) is a thyromimetic drug that binds to the thyroid hormone receptor TRβ1 preferentially compared to TRα1. It has been investigated for the treatment of dyslipidemia, obesity,[1] Pitt–Hopkins syndrome,[2] cholestatic liver disease,[3] multiple sclerosis,[4] bleomycin-induced lung fibrosis,[5] and COVID-19 caused ARDS.[6] It was designated as an orphan drug by the FDA for the treatment of X-linked adrenoleukodystrophy.[7]